Mechanisms of Action of Kefir in Chronic Cardiovascular and Metabolic Diseases.

Author: Pimenta FS1, Luaces-Regueira M2, Ton AM1, Campagnaro BP1, Campos-Toimil M2, Pereira TM1,3, Vasquez EC1
Affiliation: <sup>1</sup>Laboratory of Translational Physiology and Pharmacology, Pharmaceutical Sciences Graduate Program, Vila Velha University (UVV), Vila Velha, Brazil. <sup>2</sup>Pharmacology of Chronic Diseases (CDPHARMA), Molecular Medicine and Chronic Diseases Research Centre (CIMUS), University of Santiago de Compostela, Santiago de Compostela, Spain. <sup>3</sup>Federal Institute of Education, Science and Technology (IFES), Vila Velha, Brazil.
Conference/Journal: Cell Physiol Biochem.
Date published: 2018 Aug 9
Other: Volume ID: 48 , Issue ID: 5 , Pages: 1901-1914 , Special Notes: doi: 10.1159/000492511. [Epub ahead of print] , Word Count: 230

The gut microbiota maintains a complex mutual interaction with different organs of the host. Whereas in normal conditions this natural community of trillions of microorganisms greatly contributes to the human health, gut dysbiosis is related with onset or worsening of diverse chronic systemic diseases. Thus, the reestablishment of gut microbiota homeostasis with consumption of prebiotics and probiotics may be a relevant strategy to prevent or attenuate several cardiovascular and metabolic complications. Among these functional foods, the synbiotic kefir, which is a fermented milk composed of a mixture of bacteria and yeasts, is currently the most used and has attracted the attention of health care professionals. The present review is focused on reports describing the feasibility of kefir consumption to provide benefits in cardiometabolic diseases, including hypertension, vascular endothelial dysfunction, dyslipidemia and insulin resistance. Interestingly, recent studies show that mechanisms of actions of kefir in cardiometabolic diseases include recruitment of endothelial progenitor cells, improvement of the balance vagal/sympathetic nervous system, diminution of excessive generation of reactive oxygen species, angiotensin converting enzyme inhibition, anti-inflammatory cytokines profile and alteration of the intestinal microbiota. These findings provide a better understanding about the mechanisms of the beneficial actions of kefir and motivate further investigations to determine whether the use of this synbiotic could also be translated into clinical improvements in cardiometabolic diseases.

KEYWORDS: Atherosclerosis; Baroreflex; Dyslipidemia; Endothelial dysfunction; Hypertension; Insulin resistance; Microbiota

PMID: 30092577 DOI: 10.1159/000492511